{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:23:17Z","timestamp":1792786997782,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"Bristol-Meyers-Squibb"},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Meyers-Squibb"},{"DOI":"10.13039\/100002192","name":"LUNGevity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005923","name":"IASLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ECOG-ACRIN Foundation"},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genelux","id":[{"id":"https:\/\/ror.org\/055afwm56","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jtcvs.2018.11.124","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T12:27:22Z","timestamp":1544704042000},"page":"269-276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":262,"title":["Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"158","author":[{"given":"Matthew J.","family":"Bott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Isbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Battafarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtcvs.2018.11.124_bib1","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non\u2013small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (Checkmate 017 and Checkmate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","article-title":"Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study","volume":"36","author":"Callahan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib3","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow up of nivolumab in previously treated advanced non\u2013small-cell lung cancer: results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib4","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib5","doi-asserted-by":"crossref","first-page":"7474","DOI":"10.1158\/1078-0432.CCR-17-2005","article-title":"Immune activation in early-stage non\u2013small-cell lung cancer patients receiving neoadjuvant chemotherapy plus ipilimumab","volume":"23","author":"Yi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.athoracsur.2018.02.030","article-title":"Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors","volume":"106","author":"Bott","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib7","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.athoracsur.2017.03.038","article-title":"Initial experience with lung cancer resection after treatment with T-cell checkpoint inhibitors","volume":"104","author":"Chaft","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib8","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib10","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib11","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non\u2013small-cell lung cancer (POPLAR): a multicenter, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib12","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib13","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.athoracsur.2017.09.030","article-title":"Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non\u2013small-cell lung cancer","volume":"105","author":"Yang","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib15","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2009.26.1685","article-title":"Surgery with or without preoperative paclitaxel and carboplatin in early-stage non\u2013small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomised, phase III trial","volume":"28","author":"Pisters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib16","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.2009.27.6204","article-title":"Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non\u2013small-cell lung cancer","volume":"28","author":"Felip","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib17","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(07)60714-4","article-title":"Preoperative chemotherapy in patients with resectable non\u2013small-cell lung cancer: results of the MRC LU22\/NVALT 2\/EORTC 08012 multicentre randomised trial and update of systematic review","volume":"369","author":"Gilligan","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199401203300301","article-title":"A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non\u2013small-cell lung cancer","volume":"330","author":"Rosell","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jnci\/86.9.673","article-title":"A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non\u2013small-cell lung cancer","volume":"86","author":"Roth","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/JTO.0b013e318228a0d8","article-title":"Contemporary results of surgical resection of non\u2013small-cell lung cancer after induction therapy: a review of 549 consecutive cases","volume":"6","author":"Barnett","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib21","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/ejcts\/ezv431","article-title":"Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non\u2013small-cell lung cancer","volume":"49","author":"Yang","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/lap.2016.0540","article-title":"Video-assisted thoracoscopic lobectomy is the preferred approach following induction chemotherapy","volume":"27","author":"Kamel","year":"2017","journal-title":"J Laparoendosc Adv Tech A"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.athoracsur.2006.02.051","article-title":"Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non\u2013small-cell lung cancer","volume":"82","author":"Petersen","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib24","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.athoracsur.2017.10.056","article-title":"Neoadjuvant chemoradiation shows no survival advantage to chemotherapy alone in stage IIIA patients","volume":"105","author":"Krantz","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib25","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/JTO.0000000000000587","article-title":"Central nervous system pseudoprogression in a patient treated with PD-1 checkpoint inhibitor","volume":"10","author":"Doherty","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2016.10.014","article-title":"Report of two cases of pseudoprogression in patients with non\u2013small-cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression","volume":"102","author":"Tanizaki","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non\u2013small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtcvs.2018.11.124_bib28","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutation burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002252231833277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002252231833277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:58:54Z","timestamp":1758387534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002252231833277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S002252231833277X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2018.11.124","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735020941.793563167","asserted-by":"object"}]},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2018.11.124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Association for Thoracic Surgery","name":"copyright","label":"Copyright"}]}}